BenevolentAI S.A. (2XA.F)

0.6380 +0.0260 (+4.25%) At close: 03:29PM CEST

BenevolentAI S.A.

4-8 Maple Street
London W1T 5HD
United Kingdom
44 20 3781 9360
https://www.benevolent.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 248

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Joerg Moeller M.D., Ph.D.	CEO & Executive Director	N/A	N/A	N/A
Dr. Ivan Griffin Ph.D.	Co-Founder	350.52k	N/A	N/A
Ms. Catherine Isted A.C.M.A.	Chief Financial Officer	N/A	N/A	1975
Dr. James Malone	Chief Technology Officer	N/A	N/A	N/A
Dr. Anne Phelan	Chief Scientific Officer & Site Head for the Benevolent Cambridge Laboratories	354.2k	N/A	N/A
Ms. Fleur Wood	Vice President of Investor Relations	N/A	N/A	N/A
Mr. Will Scrimshaw	General Counsel & Company Secretary	N/A	N/A	N/A
Ms. Anna Fullerton-Batten	Chief People Officer	N/A	N/A	N/A
Mr. Tom Holgate	Senior Vice President of Finance	N/A	N/A	N/A
Ms. Christina Busmalis	Chief Revenue Officer	N/A	N/A	N/A

Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

BenevolentAI S.A. operates as a clinical-stage artificial intelligence (AI) enabled drug discovery and development company. Its Benevolent platform integrates AI and science to uncover and develop drugs for complex diseases. The company's development pipeline includes BEN-8744, an oral phosphodiesterase 10 (PDE10) inhibitor under phase 1 study for the treatment of Ulcerative Colitis; BEN-28010, an oral brain penetrant CHK1 inhibitor under preclinical study for the treatment of Glioblastoma Multiforme; BEN-34712, a preclinical candidate for the potential treatment of ALS; and various candidates for the treatment of fibrosis and Parkinson's disease. It has collaboration agreements with AstraZeneca and Merck to enhance understanding of complex disease biology and identify new targets. The company was founded in 2013 and is headquartered in London, United Kingdom.

Corporate governance

BenevolentAI S.A.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.